Home -> Law Blog Directory -> Legal Commentary Blogs -> Infamy or Praise
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Legal Commentary
: Infamy or PraiseBlawg Review Puts on the Foil
I was one of the many fans who drifted-off during the 2004-5 canceled season and never returned. These days, I don't bother to check the standings or even to watch an entire game when it's on local TV, but I'll happily watch hockey in the Olympics or in-person if given the opportunity. After the lockout year, the only hockey team I'll go out of my way to watch are the Charlestown Chiefs.
Whether you're in the camp which puts most of the blame for the lockout on then-NHLPA Executive Director (and University of Detroit Law alumnus) Bob Goodenow or the one which faults NHL Commissioner (and NYU Law alumnus) Gary Bettman, it's fair to say that lawyers killed my interest in professional hockey. With such residual bitterness, it's unlikely that lawyer R. David Donaghue could rekindle that interest, even with his fine Stanley Cup-themed Blawg Review #277 at his Chicago IP Litigation Blog site. Highlights include ponderings on pet trusts (and if you can't trust your pet, who can you trust, really?), the origins of inventions, and how best to kill a law firm.
The no doubt hockey-loving Canadian Omar Ha-Redeye will host next week's Blawg Review #278 at the Law is Cool blog.
Full post as published by Infamy or Praise on August 16, 2010 (boomark / email).
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review
Lipitor
Review of Studies Show No Significant Benefit in Women
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports









